AUSTIN, Texas / May 01, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information:
Event: | Natera’s First Quarter 2024 Financial Results |
Date: | Thursday, May 9, 2024 |
Time: | 1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In: | 1 (888) 770-7321 (Domestic) |
| 1 (929) 201-7107 (International) |
Conference ID: | 7684785 |
Webcast: | |
A webcast replay will be available at investor.natera.com. | |
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.
| Last Trade: | US$238.68 |
| Daily Change: | 8.05 3.49 |
| Daily Volume: | 977,060 |
| Market Cap: | US$32.940B |
November 12, 2025 November 06, 2025 October 28, 2025 October 20, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load